Brief Report: Pulmonary Tuberculosis Is Associated With Persistent Systemic Inflammation and Decreased HIV-1 Reservoir Markers in Coinfected Ugandans

J Acquir Immune Defic Syndr. 2018 Nov 1;79(3):407-411. doi: 10.1097/QAI.0000000000001823.

Abstract

Background: Mycobacterium tuberculosis (TB) infection induces systemic inflammation that could impact HIV-1 persistence.

Setting: HIV-1-seropositive individuals either with or without pulmonary TB disease were recruited in Kampala, Uganda.

Methods: Plasma cytokines, HIV-1 DNA, and cell-associated (ca)-RNA were compared among those coinfected with TB (cases) to those without TB (controls). TB-coinfected cases and controls were compared at presentation (n = 15 and n = 16, respectively) and at around 6 months after HIV-1 treatment initiation among those who had achieved virologic suppression (n = 6 and n = 8, respectively). At follow-up, the TB-coinfected cases had also finished TB treatment.

Results: Before treatment, the TB-coinfected cases as compared to the controls had higher levels of soluble(s)-CD163 (P = 0.0002) and interleukin-6 (P = 0.006) but lower levels of macrophage chemoattractant protein-1 (P = 0.04). After treatment, the TB-coinfected cases as compared to controls still had higher plasma s-CD163 levels (P = 0007). Controls as compared to the coinfected cases had higher ca-RNA per DNA template both at baseline (P = 0.03) and at follow-up (P = 0.07). Levels of ca-RNA per DNA copy at follow-up showed a negative correlation with baseline plasma s-CD163 (P = 0.008) and interleukin-6 (P = 0.05) levels.

Conclusions: TB disease is associated with inflammation and decreased HIV-1 RNA expression relative to the number of infected cells, both before and after viral suppression. Infections present before antiretroviral initiation impact HIV-1 latency.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Anti-HIV Agents / therapeutic use
  • Antitubercular Agents / therapeutic use
  • Coinfection / pathology*
  • Cytokines / blood
  • DNA, Viral / analysis
  • Female
  • Follow-Up Studies
  • HIV Infections / complications
  • HIV Infections / drug therapy
  • HIV Infections / pathology*
  • HIV-1 / isolation & purification*
  • Humans
  • Inflammation / pathology*
  • Male
  • Middle Aged
  • Plasma / chemistry
  • RNA, Viral / analysis
  • Tuberculosis, Pulmonary / complications
  • Tuberculosis, Pulmonary / pathology*
  • Uganda
  • Viral Load*
  • Virus Latency*
  • Young Adult

Substances

  • Anti-HIV Agents
  • Antitubercular Agents
  • Cytokines
  • DNA, Viral
  • RNA, Viral